Spruce Biosciences Inc. (SPRB)
Spruce Biosciences Statistics
Share Statistics
Spruce Biosciences has 41.3M shares outstanding. The number of shares has increased by 0.36% in one year.
| Shares Outstanding | 41.3M |
| Shares Change (YoY) | 0.36% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 27.03% |
| Shares Floating | 29.2M |
| Failed to Deliver (FTD) Shares | 355 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 136.39K, so 0.33% of the outstanding shares have been sold short.
| Short Interest | 136.39K |
| Short % of Shares Out | 0.33% |
| Short % of Float | 0.35% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.33 and the forward PE ratio is -0.19. Spruce Biosciences's PEG ratio is -0.08.
| PE Ratio | -0.33 |
| Forward PE | -0.19 |
| PS Ratio | 3.53 |
| Forward PS | 0.3 |
| PB Ratio | 0.6 |
| P/FCF Ratio | -0.31 |
| PEG Ratio | -0.08 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Spruce Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.9, with a Debt / Equity ratio of 0.08.
| Current Ratio | 2.9 |
| Quick Ratio | 2.9 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | -0.04 |
| Debt / FCF | -0.04 |
| Interest Coverage | 182.9 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $233.86K |
| Profits Per Employee | $-2.53M |
| Employee Count | 21 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -82.88% in the last 52 weeks. The beta is 2.39, so Spruce Biosciences's price volatility has been higher than the market average.
| Beta | 2.39 |
| 52-Week Price Change | -82.88% |
| 50-Day Moving Average | 0.34 |
| 200-Day Moving Average | 0.44 |
| Relative Strength Index (RSI) | 18.76 |
| Average Volume (20 Days) | 875.09K |
Income Statement
In the last 12 months, Spruce Biosciences had revenue of 4.91M and earned -53.04M in profits. Earnings per share was -1.29.
| Revenue | 4.91M |
| Gross Profit | 4.91M |
| Operating Income | -56.15M |
| Net Income | -53.04M |
| EBITDA | -56.15M |
| EBIT | -53.34M |
| Earnings Per Share (EPS) | -1.29 |
Balance Sheet
The company has 38.75M in cash and 2.36M in debt, giving a net cash position of 36.4M.
| Cash & Cash Equivalents | 38.75M |
| Total Debt | 2.36M |
| Net Cash | 36.4M |
| Retained Earnings | -250.27M |
| Total Assets | 65.1M |
| Working Capital | 51.72M |
Cash Flow
In the last 12 months, operating cash flow was -55.96M and capital expenditures 0, giving a free cash flow of -55.96M.
| Operating Cash Flow | -55.96M |
| Capital Expenditures | 0 |
| Free Cash Flow | -55.96M |
| FCF Per Share | -1.36 |
Margins
Gross margin is 100%, with operating and profit margins of -1143.37% and -1079.94%.
| Gross Margin | 100% |
| Operating Margin | -1143.37% |
| Pretax Margin | -1079.94% |
| Profit Margin | -1079.94% |
| EBITDA Margin | -1143.37% |
| EBIT Margin | -1143.37% |
| FCF Margin | -1139.56% |
Dividends & Yields
SPRB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for SPRB is $1.75, which is 1358.3% higher than the current price. The consensus rating is "Hold".
| Price Target | $1.75 |
| Price Target Difference | 1358.3% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -5.21 |
| Piotroski F-Score | 4 |